{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:16:18Z","timestamp":1648772178445},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.medcli.2013.11.009","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T06:10:04Z","timestamp":1388815804000},"page":"275-280","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Terapia biol\u00f3gica en pacientes con miopat\u00eda inflamatoria idiop\u00e1tica"],"prefix":"10.1016","volume":"143","author":[{"given":"Albert","family":"Selva-O\u2019Callaghan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Ramos Casals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Grau Junyent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2013.11.009_bib0005","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis, and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.11.009_bib0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/WCO.0b013e328357f211","article-title":"Pathogenesis and therapy of inclusion body myositis","volume":"25","author":"Greenberg","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0015","first-page":"CD003643","article-title":"Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis","volume":"8","author":"Gordon","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2013.11.009_bib0020","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3899\/jrheum.120682","article-title":"Classification, diagnosis, and management of idiopathic inflammatory myopathies","volume":"40","author":"Lazarou","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrrheum.2010.2","article-title":"Immunotherapy of myositis: Issues, concerns and future prospects","volume":"6","author":"Dalakas","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/BOR.0b013e328358ac72","article-title":"Therapeutic advances in myositis","volume":"24","author":"Aggarwal","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mayocp.2012.10.017","article-title":"Idiopathic inflammatory myopathies: Current trends in pathogenesis, clinical features, and up-to-date treatment recommendations","volume":"88","author":"Ernste","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.medcli.2013.11.009_bib0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: An update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.medcli.2013.11.009_bib0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00000441-200302000-00005","article-title":"New indications for treatment of chronic inflammation by TNF-alpha blockade","volume":"325","author":"Reimold","year":"2003","journal-title":"Am J Med Sci"},{"issue":"Suppl 3","key":"10.1016\/j.medcli.2013.11.009_bib0050","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1186\/ar564","article-title":"Perspectives for TNF-alpha-targeting therapies","volume":"4","author":"Lorenz","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.medcli.2013.11.009_bib0055","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1157\/13113285","article-title":"Polymyositis-dermatomyositis: Incidence in Spain (1997-2004)","volume":"129","author":"Vargas-Legu\u00e1s","year":"2007","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0065","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.11.009_bib0070","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/art.37758","article-title":"The efficacy of rituximab in refractory myositis: The jury is still out","volume":"65","author":"De Visser","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/keg427","article-title":"International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease","volume":"43","author":"Isenberg","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 11","key":"10.1016\/j.medcli.2013.11.009_bib0085","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0090","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0095","unstructured":"International Myositis Assessment and Clinical Studies Group (IMACS). Disponible en: https:\/\/dirapps.niehs.nih.gov\/imacs\/"},{"key":"10.1016\/j.medcli.2013.11.009_bib0100","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/art.20349","article-title":"International consensus on preliminary definitions of improvement in adult and juvenile myositis","volume":"50","author":"Rider","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1573397054023173","article-title":"Specific biologic therapy with tumor necrosis factor inhibitors in patients with inflammatory myopathy","volume":"1","author":"Selva-O\u2019Callaghan","year":"2005","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.medcli.2013.11.009_bib0110","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.medcli.2010.02.032","article-title":"Biologic agents in myositis: Unsolved questions","volume":"135","author":"Grau","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0115","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/art.1780400514","article-title":"Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies","volume":"40","author":"Lundberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s004010051165","article-title":"Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis","volume":"99","author":"Kuru","year":"2000","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0125","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8","article-title":"TNF alpha-308A allele in juvenile dermatomyositis: Association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications","volume":"43","author":"Pachman","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s100670070027","article-title":"Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis","volume":"19","author":"Shimizu","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0135","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/ard.2007.077974","article-title":"A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies","volume":"67","author":"Dastmalchi","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.medcli.2013.11.009_bib0140","first-page":"S2058","article-title":"A randomized, double-blind, placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis","volume":"58","author":"Coyle","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A randomized, pilot trial of etanercept in dermatomyositis","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0150","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ana.22624","article-title":"Etanercept as steroid-sparing agent in dermatomyositis","volume":"70","author":"Giovanna Brunasso","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0155","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.medcli.2010.03.016","article-title":"B-cell-depletion therapy in systemic autoimmune diseases. Recommendations for use in clinical practice","volume":"136","author":"Ramos-Casals","year":"2011","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: An open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0165","first-page":"1009","article-title":"Rituximab in the treatment of dermatomyositis and other inflammatory myopathies: A report of 4 cases and review of the literature","volume":"27","author":"Rios Fern\u00e1ndez","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0170","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: A case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0175","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.medcli.2009.12.022","article-title":"Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy","volume":"135","author":"Garc\u00eda Hern\u00e1ndez","year":"2010","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0180","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3899\/jrheum.101321","article-title":"Safety and efficacy of rituximab in severe juvenile dermatomyositis: Results from 9 patients from the French Autoimmunity and Rituximab registry","volume":"38","author":"Bader-Meunier","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0185","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.medcli.2013.11.009_bib0190","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0195","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/ncprheum0140","article-title":"Mechanisms of disease: Signaling pathways and immunobiology of inflammatory myopathies","volume":"2","author":"Dalakas","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.medcli.2013.11.009_bib0200","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.medcli.2013.11.009_bib0205","first-page":"S489","article-title":"A pilot study of eculizumab in patients with dermatomyositis","volume":"46","author":"Takada","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0210","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.medcli.2013.11.009_bib0215","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1093\/brain\/awp275","article-title":"Comment on alemtuzumab and inclusion body myositis","volume":"133","author":"Greenberg","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.medcli.2013.11.009_bib0220","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/art.22388","article-title":"Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies","volume":"56","author":"Grundtman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0225","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/art.34465","article-title":"Interleukin-1 and tumor necrosis factor \u03b1 blockade treatment of experimental polymyositis in mice","volume":"64","author":"Sugihara","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.medcli.2013.11.009_bib0230","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2007.07.010","article-title":"Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report","volume":"75","author":"Furlan","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.medcli.2013.11.009_bib0235","article-title":"Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: A mechanistic study with 12 months follow-up","author":"Zong","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.medcli.2013.11.009_bib0240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): A small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.medcli.2013.11.009_bib0245","first-page":"33","article-title":"Treatment of refractory primary inflammatory myopathies with biological therapy clinical experience in 47 patients: BIOGEAS registry","volume":"212","author":"D\u00edaz Lagares","year":"2012","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.medcli.2013.11.009_bib0250","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.11.009_bib0255","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2013.11.009_bib0260","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313008397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775313008397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,7]],"date-time":"2018-10-07T17:23:35Z","timestamp":1538933015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775313008397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0025775313008397"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2013.11.009","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Terapia biol\u00f3gica en pacientes con miopat\u00eda inflamatoria idiop\u00e1tica","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2013.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}